A
Anne-Geneviève Marcelin
Researcher at University of Paris
Publications - 397
Citations - 11260
Anne-Geneviève Marcelin is an academic researcher from University of Paris. The author has contributed to research in topics: Medicine & Viral load. The author has an hindex of 52, co-authored 339 publications receiving 9524 citations. Previous affiliations of Anne-Geneviève Marcelin include École normale supérieure de Cachan & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover
Jorge R. Almeida,David Price,David Price,Laura Papagno,Zaïna Aït Arkoub,Delphine Sauce,Ethan Bornstein,Tedi E. Asher,Assia Samri,Aurélie Schnuriger,Ioannis Theodorou,Dominique Costagliola,Christine Rouzioux,Henri Agut,Anne-Geneviève Marcelin,Daniel C. Douek,Brigitte Autran,Victor Appay +17 more
TL;DR: It is shown that B27-KK10–specific CD8+ T cells are characterized by polyfunctional capabilities, increased clonal turnover, and superior functional avidity, which constitute the basis for effective control of HIV-1 replication.
Journal ArticleDOI
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Ana Canestri,Franæois-Xavier Lescure,Stéphane Jauréguiberry,Antoine Moulignier,Corinne Amiel,Anne-Geneviève Marcelin,Anne-Geneviève Marcelin,Gilles Peytavin,Roland Tubiana,Gilles Pialoux,Christine Katlama,Christine Katlama +11 more
TL;DR: Despite successful suppression of plasma viremia with antiretroviral therapy, HIV may replicate in CSF, with development of CSF HIV resistance resulting in acute or subacute neurological manifestations.
Journal ArticleDOI
Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro
Isabelle Malet,Olivier Delelis,Marc-Antoine Valantin,Brigitte Montes,Cathia Soulié,Marc Wirden,Luba Tchertanov,Gilles Peytavin,Jacques Reynes,Jean-François Mouscadet,Christine Katlama,Vincent Calvez,Anne-Geneviève Marcelin +12 more
TL;DR: Raltegravir is a potent inhibitor of human immunodeficiency virus (HIV) integrase and is clinically effective against viruses resistant to other classes of antiretroviral agents, however, it can select mutations in the HIV integrase gene that led to strong impairment of enzymes in vitro in the absence of ralteGravir.
Journal ArticleDOI
Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial
Collins Iwuji,Collins Iwuji,Joanna Orne-Gliemann,Joseph Larmarange,Eric Balestre,Rodolphe Thiébaut,Frank Tanser,Nonhlanhla Okesola,Thembisa Makowa,Jaco Dreyer,Kobus Herbst,Nuala McGrath,Nuala McGrath,Till Bärnighausen,Till Bärnighausen,Sylvie Boyer,Tulio de Oliveira,Claire Rekacewicz,Brigitte Bazin,Marie-Louise Newell,Deenan Pillay,François Dabis,Collins Iwuji,Kevi Naidu,Tamsen J. Rochat,Johannes Henning Viljoen,Thembelihle Zuma,Sophie Karcher,Melanie Plazy,Mélanie Prague,Thierry Tiendrebeogo,Hermann Donfouet,Andréa Gosset,Laura March,Camelia Protopopescu,Bruno Spire,Alexandra Calmy,Maxime Inghels,Hassimiou Diallo,Vincent Calvez,Anne Derache,Anne-Geneviève Marcelin,Rosemary Dray-Spira,Kamal El Farouki,Richard J Lessells,Kenneth A. Freedberg,John Imrie,Marie-Laure Chaix,Colin Newell,Jan A. C. Hontelez +49 more
TL;DR: In this paper, the effect of universal test and treat on HIV acquisition at population level in a high prevalence rural region of South Africa was investigated in a phase 4, open-label, cluster randomised trial of 22 communities in rural KwaZulu-Natal, South Africa.
Journal ArticleDOI
Tetherin Restricts Productive HIV-1 Cell-to-Cell Transmission
Nicoletta Casartelli,Marion Sourisseau,Jérôme Feldmann,Florence Guivel-Benhassine,Adeline Mallet,Anne-Geneviève Marcelin,John C. Guatelli,Olivier Schwartz +7 more
TL;DR: It is shown that tetherin inhibits productive cell-to-cell transmission of ΔVpu to targets and impairs that of WT HIV, the first example of a surface restriction factor limiting viral cell- to-cell spread.